The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9879074 B1

PDF
Full Text
Expired
Date of Patent:
Jan. 30, 2018

Filed:

May. 29, 2015
Applicant:

Alderbio Holdings Llc, Las Vegas, NV (US);

Inventors:

Leon F. Garcia-Martinez, Woodinville, WA (US);

Anne Elisabeth Carvalho Jensen, Snohomish, WA (US);

Katie Anderson, Kirkland, WA (US);

Benjamin H. Dutzar, Seattle, WA (US);

Ethan W. Ojala, Snohomish, WA (US);

Brian R. Kovacevich, Snohomish, WA (US);

John A. Latham, Seattle, WA (US);

Jeffrey T. L. Smith, Bellevue, WA (US);

Assignee:

ALDERBIO HOLDINGS LLC, Las Vegas, NV (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/20 (2006.01); A61K 39/395 (2006.01); C07K 16/18 (2006.01); C07K 16/24 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 39/39533 (2013.01); A61K 45/06 (2013.01); C07K 16/248 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2316/96 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/41 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.


Find Patent Forward Citations

Quick Actions:

Garcia-Martinez, Leon. (2018). Antibodies to il-6 and use thereof (U.S. Patent No. 9879074). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/9879074

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…